Lemierre's syndrome with double heterozygote status in the methylenetetrahydrofolate reductase gene.

Abstract

BACKGROUND:

There are some risk factors being more vulnerable to Lemierre's syndrome such as a hypercoagulable state.

METHODS:

We report a rare case of Lemierre's syndrome with ethmoid and maxillary sinusitis, bilateral mastoiditis, and sigmoid sinus thrombosis.

RESULTS:

Genetic study revealed a double heterozygote status in the methylenetetrahydrofolate reductase gene including C677T and A1298C.

CONCLUSION:

It is suggested to screen patients with Lemierre's syndrome for a hypercoagulable state to consider anticoagulant therapy.

• Authors: Mostafa Behpour-Oskooee, Abdollah Karimi, Shirin Sayyahfar
• Journal: World journal of pediatrics : WJP (World J Pediatr) Vol. 10 Issue 3 Pg. 281-3 (Aug 2014) ISSN: 1867-0687 [Electronic] Switzerland
• PMID: 24668238 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Anticoagulants
• Biomarkers
• Heparin, Low-Molecular-Weight
• Clindamycin
• Ceftriaxone
• Methylenetetrahydrofolate Reductase (NADPH2)

Topics

• Anti-Bacterial Agents (therapeutic use)
• Anticoagulants (therapeutic use)
• Biomarkers (blood)
• Ceftriaxone (therapeutic use)
• Child
• Clindamycin (therapeutic use)
• Drug Therapy, Combination
• Heparin, Low-Molecular-Weight (therapeutic use)
• Heterozygote
• Humans
• Lemierre Syndrome (diagnosis, drug therapy, genetics)
• Male
• Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
• Treatment Outcome